PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: ZOLL Medical Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ZOLL LifeVest, AutoPulse and Temperature Management Solutions to be Showcased at TCT 2013 - ZOLL Medical Corporation announced that it will display the LifeVest® Wearable Defibrillator, the AutoPulse® Non-invasive Cardiac Support Pump, and ZOLL’s Intravascular Temperature Management (IVTM™) solution - ZOLL.com
ZOLL LifeVest, AutoPulse and Temperature Management Solutions to be Showcased at TCT 2013

 

NewswireToday - /newswire/ - Chelmsford, MA, United States, 2013/10/25 - ZOLL Medical Corporation announced that it will display the LifeVest® Wearable Defibrillator, the AutoPulse® Non-invasive Cardiac Support Pump, and ZOLL’s Intravascular Temperature Management (IVTM™) solution - ZOLL.com. NASDAQ: ZOLL

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will display the LifeVest® Wearable Defibrillator, the AutoPulse® Non-invasive Cardiac Support Pump, and ZOLL’s Intravascular Temperature Management (IVTM™) solution in booth #429 at the 2013 Transcatheter Cardiovascular Therapeutics (TCT) meeting October 29-November 1 at the Moscone Center in San Francisco.

Following a percutaneous coronary intervention (PCI) procedure, 1 in 5 post-acute myocardial infarction (AMI) patients have been shown to be at high risk of early mortality.1 The majority of mortality in AMI patients post-PCI occurs in the first three months one out of every 10 high risk patients die, with about 60% of this mortality due to sudden cardiac arrest (SCA).1,2 Data has shown that in patients treated by the LifeVest Wearable Cardioverter Defibrillator, the median time to shock following revascularization is 14 days.3 Additionally, LifeVest use post-PCI is associated with an 85% reduction in total mortality at 90 days compared to a matched cohort of patients not prescribed the LifeVest.4

The LifeVest is worn by patients at risk for SCA, providing protection during their changing condition and while permanent SCA risk has not been established. It is used to protect a wide range of patient conditions or situations, including following a recent myocardial infarction, or following coronary revascularization.

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.

The AutoPulse is an automated, portable chest compression device. It is the only mechanical CPR system to have shown improved survival in comparative clinical trials. The AutoPulse more than tripled survival compared to typical CPR during witnessed shockable arrests.5 Most recently a meta-analysis of available clinical findings found that the likelihood of circulation returning was 62% higher with use of the AutoPulse when compared to manual compressions while a parallel analysis showed no significant change with a conventional piston-driven device.6

ZOLL’s Intravascular Temperature Management (IVTM) solution offers health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. The Thermogard XP® delivers accurate, easy-to-use and cost-effective control for both cooling and warming applications.

About ZOLL Medical Corporation
ZOLL Medical Corporation (zoll.com), an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

About Asahi Kasei
The Asahi Kasei Group (asahi-kasei.co.jp) is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 25,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.

Copyright © 2013 ZOLL Medical Corporation. All rights reserved. AutoPulse, IVTM, LifeVest, Thermogard XP, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All product names are the property of their respective owners.

1 Halkin, A, et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: CADILLAC Risk Score. Journal of the American College of Cardiology, 2005; 45: 1397-1405.
2 Stone, G, et al. “Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients.” April 2011.
3 Epstein, A, et al. Wearable Cardioverter-Defibrillator Use in Patients Perceived to be at High Risk Early Post Myocardial Infarction, Journal of the American College of Cardiology 2013, doi:10.1016/j.jacc.2013.05.086.
4 Zishiri, E, et al. Early Risk of Mortality after Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction and Potential Role of the Wearable Cardioverter Defibrillator. Circulation: Arrhythmia and Electrophysiology; 2013;6: 117-128.
5 Wik L, et al. The impact of CPR duration on survival to discharge between integrated AutoPulse-CPR and manual CPR during out-of-hospital cardiac arrest of presumed cardiac origin. Resuscitation. 2012;83:e17
6 Westfall et al. Mechanical versus manual chest compressions in out-of-hospital-cardiac arrest. Critical Care Medicine. 2013;41:1-7.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: ZOLL Medical Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


ZOLL LifeVest, AutoPulse and Temperature Management Solutions to be Showcased at TCT 2013

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Diane Egan - ZOLL.com 
978-421-9637 degan[.]zoll.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ZOLL Medical Corporation securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From ZOLL Medical Corporation / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Frost & Sullivan Lauds SnooZeal’s Unique Electrical Stimulation Therapy for Sleep Apnea in the European Market
ZOLL Expands the Rescuer Experience at EMS Today
Traditional Mass Spectrometers Give Way to High-resolution Technologies Such as MALDI-TOF Finds Frost & Sullivan
AccuVein, Inc. Named A Best Place to Work in Medical Sales for Second Consecutive Year
MRI Inventor to Receive the Medtech Innovation Catalyst Award
Ansell Limited Acquires Cleanroom and Healthcare Consumables Manufacturer Nitritex Limited
ZOLL to Showcase Expanded Portfolio of Advanced Resuscitation and Acute Critical Care Technologies at Arab Health 2017
Frost & Sullivan Awards Ansell for Entrenching itself in the Hand Protection Market with its Visionary Products and Technologies
ZOLL RescueNet ePCR Achieves Latest National Compliance Standard
Eye Tech Care Wins Top Honours from Frost & Sullivan for Developing the EyeOP1, the Only Computer-assisted System for Glaucoma Therapy
Frost & Sullivan Recognizes Nuvectra’s Pioneering Spinal Cord Stimulation Product for Chronic Pain Management
GE Healthcare to Commercialize Rapiscan® Outside the US, Canada & Mexico for Increased Access to Heart Exams
Novel Home Care Needs and Customer Preferences Catalyse Growth Opportunities in Mature Cardiac Monitoring Market Finds Frost & Sullivan
Frost & Sullivan Highlights Inspirata's Leading-edge Digital Pathology Solutions that Accelerate Cancer Diagnostics, Monitoring, Treatment
Sparta Systems Broadens Partnership with TrackWise Implementation Specialist Equality Systems

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)